Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD69 molecule (CD69)
- Target
- CD69
- Molecular classification
- C-type lectin domain receptor, Type II transmembrane glycoprotein, CD molecule (Cluster of Differentiation)
01
Overview
CD69 molecule is a type II transmembrane C-type lectin domain receptor rapidly expressed on the surface of T-lymphocytes, NK cells, B cells, and platelets following immune activation. It serves as one of the earliest markers of lymphocyte activation and directly regulates cell trafficking by interacting with the sphingosine-1-phosphate receptor 1 (S1P1), retaining activated lymphocytes within lymphoid tissues to support effective immune responses. CD69 modulates diverse intracellular signaling pathways—such as JAK/STAT, mTOR, and ERK1/2—to influence processes like Th17 or regulatory T cell differentiation, immune tolerance, and inflammation. It is implicated in autoimmunity, infection, and as a potential functional target for monoclonal antibody-mediated therapies in immunological research.
- Other names
- Early activation antigen CD69CLEC2CAIMBL-AC/P26C-type lectin domain family 2 member CEA1Early T-cell activation antigen p60GP32/28Leukocyte surface antigen Leu-23MLR-3
02
Mechanism of action
Antibody-mediated blockade or depletion of CD69-expressing cells; Modulation of S1P1-mediated lymphocyte egress from lymphoid organs; Alteration of downstream JAK/STAT, NFAT, or ERK1 signaling
03
Biological functions
Immune cell activation markerSignal transduction (in lymphocytes, NK cells, and platelets)Regulation of lymphocyte trafficking and retention in lymphoid organs (via S1P1 interaction)Regulation of Th17 and regulatory T cell differentiationNegative regulation of inflammatory responsesPromotion of cell homeostasis and memory Th cell persistence
04
Disease associations
InflammationAutoimmune disease (notably type 1 diabetes)InfectionPotential role in cancer (by modulating immune cell trafficking, though not directly established in provided results)Eosinophilic pneumoniaCoccidioidomycosis
05
Safety considerations
Potential for immunosuppression or impairment of memory T cell responses when targeting CD69Modulation of cell trafficking may affect immune surveillance or tolerance, posing risks for infection or autoimmunity
06
Interacting drugs
Anti-CD69 monoclonal antibodies (experimental, used primarily in research for depleting/alterating CD69-expressing cell activity in vivo)
07
Biomarkers
CD69 surface expression as a marker of early T/NK/B cell activation in blood and tissueCD69+CD4+ regulatory T cells as markers of regulatory activity or dysfunction in autoimmune diseases
Beyond the preview
Go deeper on CD69 molecule (CD69).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD69 molecule (CD69).